1
|
Lamoureux L, Beverley JA, Marinelli M, Steiner H. Fluoxetine potentiates methylphenidate-induced behavioral responses: Enhanced locomotion or stereotypies and facilitated acquisition of cocaine self-administration. ADDICTION NEUROSCIENCE 2023; 9:100131. [PMID: 38222942 PMCID: PMC10785378 DOI: 10.1016/j.addicn.2023.100131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/16/2024]
Abstract
The medical psychostimulant methylphenidate (MP) is used to treat attention-deficit hyperactivity disorder and recreationally as a "cognitive enhancer". MP is a dopamine reuptake inhibitor, but does not affect serotonin. Serotonin contributes to addiction-related gene regulation and behavior. Previously, we showed that enhancing serotonin action by adding a selective serotonin reuptake inhibitor, fluoxetine (FLX), to MP potentiates MP-induced gene regulation in striatum and nucleus accumbens, mimicking cocaine effects. Here, we investigated the behavioral consequences of MP+FLX treatment. Young adult male rats received MP (5 mg/kg, i.p.) or MP+FLX (5 mg/kg each) daily for 6-8 days. Behavioral effects were assessed in an open-field test during the repeated treatment. Two weeks later the motor response to a cocaine challenge (25 mg/kg) and the rate of acquisition of cocaine self-administration behavior were determined. Our results demonstrate that FLX potentiates effects of MP on open-field behavior. However, we found differential behavioral responses to MP+FLX treatment, as approximately half of the rats developed high rates of focal stereotypies (termed "MP+FLX/high reactivity" group), whereas the other half did not, and only showed increased locomotion ("MP+FLX/low reactivity" group). Two weeks later, cocaine-induced locomotion and stereotypies were positively correlated with MP+FLX-induced behavior seen at the end of the repeated MP+FLX treatment. Moreover, the MP+FLX/high reactivity group, but not the low reactivity group, showed facilitated acquisition of cocaine self-administration. These results demonstrate that repeated MP+FLX treatment can facilitate subsequent cocaine taking behavior in a subpopulation of rats. These findings suggest that MP+FLX exposure in some individuals may increase the risk for psychostimulant use later in life.
Collapse
Affiliation(s)
- Lorissa Lamoureux
- Discipline of Cellular and Molecular Pharmacology, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA
- Present address: Biologic Resources Laboratory, University of Illinois at Chicago, Chicago, IL 60612, USA
| | - Joel A. Beverley
- Discipline of Cellular and Molecular Pharmacology, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA
| | - Michela Marinelli
- Discipline of Cellular and Molecular Pharmacology, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA
- Present address: Department of Neuroscience, The University of Texas at Austin, Austin, TX 78712, USA
| | - Heinz Steiner
- Discipline of Cellular and Molecular Pharmacology, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA
- Stanson Toshok Center for Brain Function and Repair, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA
| |
Collapse
|
2
|
Mechler K, Banaschewski T, Hohmann S, Häge A. Evidence-based pharmacological treatment options for ADHD in children and adolescents. Pharmacol Ther 2021; 230:107940. [PMID: 34174276 DOI: 10.1016/j.pharmthera.2021.107940] [Citation(s) in RCA: 61] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Accepted: 05/06/2021] [Indexed: 12/15/2022]
Abstract
Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity, causing functional impairment. Its prevalence lies at approximately 5% in children and adolescents and at approximately 2.5% in adults. The disorder follows a multifactorial etiology and shows a high heritability. Patients show a high interindividual and intraindividual variability of symptoms, with executive deficits in several cognitive domains. Overall, ADHD is associated with high rates of psychiatric comorbidities, and insufficient treatment is linked to adverse long-term outcomes. Current clinical guidelines recommend an individualized multimodal treatment approach including psychoeducation, pharmacological interventions, and non-pharmacological interventions. Available medications include stimulants (methylphenidate, amphetamines) and non-stimulants (atomoxetine, guanfacine, clonidine). While available pharmacological treatment options for ADHD show relatively large effect sizes (in short-term trials) and overall good tolerability, there is still a need for improvement of current pharmacotherapeutic strategies and for the development of novel medications. This review summarizes available pharmacological treatment options for ADHD in children and adolescents, identifies current issues in research and evidence gaps, and provides an overview of ongoing efforts to develop new medications for the treatment of ADHD in children and adolescents by means of a systematic cross-sectional analysis of the clinical trials registry www.clinicaltrials.gov.
Collapse
Affiliation(s)
- Konstantin Mechler
- Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
| | - Tobias Banaschewski
- Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Sarah Hohmann
- Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Alexander Häge
- Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| |
Collapse
|
3
|
Matthijssen AFM, Dietrich A, Bierens M, Kleine Deters R, van de Loo-Neus GHH, van den Hoofdakker BJ, Buitelaar JK, Hoekstra PJ. Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study. Am J Psychiatry 2019; 176:754-762. [PMID: 31109200 DOI: 10.1176/appi.ajp.2019.18111296] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE The benefits of long-term use of methylphenidate treatment in children and adolescents with attention deficit hyperactivity disorder (ADHD), as frequently prescribed in clinical practice, are unclear. The authors investigated whether methylphenidate remains beneficial after 2 years of use. METHODS Ninety-four children and adolescents (ages 8-18 years) who had been treated in regular care with methylphenidate for more than 2 years were randomly assigned to double-blind continuation of treatment for 7 weeks (36 or 54 mg/day of extended-release methylphenidate) or gradual withdrawal over 3 weeks, to 4 weeks of placebo. The primary outcome measure was the investigator-rated ADHD Rating Scale (ADHD-RS); secondary outcome measures were the investigator-rated Clinical Global Impressions improvement scale (CGI-I) and the Conners' Teacher Rating Scale-Revised: Short Form (CTRS-R:S). Continuous ratings were analyzed with mixed model for repeated measures analyses, and the CGI-I with a chi-square test. RESULTS The mean ADHD-RS scores at baseline for the continuation and discontinuation groups, respectively, were 21.4 (SD=9.7) and 19.6 (SD=8.9); after 7 weeks, the mean scores were 21.9 (SD=10.8) and 24.7 (SD=11.4), with a significant between-group difference in change over time of -4.6 (95% CI=-8.7, -0.56) in favor of the group that continued methylphenidate treatment. The ADHD-RS inattention subscale and the CTRS-R:S ADHD index and hyperactivity subscale also deteriorated significantly more in the discontinuation group. The CGI-I indicated worsening in 40.4% of the discontinuation group, compared with 15.9% of the continuation group. CONCLUSIONS Continued treatment with methylphenidate remains effective after long-term use. Some individual patients may, however, be withdrawn from methylphenidate without deterioration. This finding supports guideline recommendations that patients be assessed periodically to determine whether there is a continued need for methylphenidate treatment.
Collapse
Affiliation(s)
- Anne-Flore M Matthijssen
- The Department of Child and Adolescent Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (Matthijssen, Dietrich, Kleine Deters, Van den Hoofdakker, Hoekstra); the Karakter Child and Adolescent Psychiatry Center Nijmegen, Nijmegen, the Netherlands (Bierens, Van de Loo-Neus); the Department of Clinical Psychology and Experimental Psychopathology, University of Groningen, Groningen, the Netherlands (Van den Hoofdakker); and the Donders Institute for Brain, Cognition, and Behavior and the Department of Cognitive Neuroscience, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands (Buitelaar)
| | - Andrea Dietrich
- The Department of Child and Adolescent Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (Matthijssen, Dietrich, Kleine Deters, Van den Hoofdakker, Hoekstra); the Karakter Child and Adolescent Psychiatry Center Nijmegen, Nijmegen, the Netherlands (Bierens, Van de Loo-Neus); the Department of Clinical Psychology and Experimental Psychopathology, University of Groningen, Groningen, the Netherlands (Van den Hoofdakker); and the Donders Institute for Brain, Cognition, and Behavior and the Department of Cognitive Neuroscience, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands (Buitelaar)
| | - Margreet Bierens
- The Department of Child and Adolescent Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (Matthijssen, Dietrich, Kleine Deters, Van den Hoofdakker, Hoekstra); the Karakter Child and Adolescent Psychiatry Center Nijmegen, Nijmegen, the Netherlands (Bierens, Van de Loo-Neus); the Department of Clinical Psychology and Experimental Psychopathology, University of Groningen, Groningen, the Netherlands (Van den Hoofdakker); and the Donders Institute for Brain, Cognition, and Behavior and the Department of Cognitive Neuroscience, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands (Buitelaar)
| | - Renee Kleine Deters
- The Department of Child and Adolescent Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (Matthijssen, Dietrich, Kleine Deters, Van den Hoofdakker, Hoekstra); the Karakter Child and Adolescent Psychiatry Center Nijmegen, Nijmegen, the Netherlands (Bierens, Van de Loo-Neus); the Department of Clinical Psychology and Experimental Psychopathology, University of Groningen, Groningen, the Netherlands (Van den Hoofdakker); and the Donders Institute for Brain, Cognition, and Behavior and the Department of Cognitive Neuroscience, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands (Buitelaar)
| | - Gigi H H van de Loo-Neus
- The Department of Child and Adolescent Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (Matthijssen, Dietrich, Kleine Deters, Van den Hoofdakker, Hoekstra); the Karakter Child and Adolescent Psychiatry Center Nijmegen, Nijmegen, the Netherlands (Bierens, Van de Loo-Neus); the Department of Clinical Psychology and Experimental Psychopathology, University of Groningen, Groningen, the Netherlands (Van den Hoofdakker); and the Donders Institute for Brain, Cognition, and Behavior and the Department of Cognitive Neuroscience, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands (Buitelaar)
| | - Barbara J van den Hoofdakker
- The Department of Child and Adolescent Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (Matthijssen, Dietrich, Kleine Deters, Van den Hoofdakker, Hoekstra); the Karakter Child and Adolescent Psychiatry Center Nijmegen, Nijmegen, the Netherlands (Bierens, Van de Loo-Neus); the Department of Clinical Psychology and Experimental Psychopathology, University of Groningen, Groningen, the Netherlands (Van den Hoofdakker); and the Donders Institute for Brain, Cognition, and Behavior and the Department of Cognitive Neuroscience, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands (Buitelaar)
| | - Jan K Buitelaar
- The Department of Child and Adolescent Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (Matthijssen, Dietrich, Kleine Deters, Van den Hoofdakker, Hoekstra); the Karakter Child and Adolescent Psychiatry Center Nijmegen, Nijmegen, the Netherlands (Bierens, Van de Loo-Neus); the Department of Clinical Psychology and Experimental Psychopathology, University of Groningen, Groningen, the Netherlands (Van den Hoofdakker); and the Donders Institute for Brain, Cognition, and Behavior and the Department of Cognitive Neuroscience, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands (Buitelaar)
| | - Pieter J Hoekstra
- The Department of Child and Adolescent Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (Matthijssen, Dietrich, Kleine Deters, Van den Hoofdakker, Hoekstra); the Karakter Child and Adolescent Psychiatry Center Nijmegen, Nijmegen, the Netherlands (Bierens, Van de Loo-Neus); the Department of Clinical Psychology and Experimental Psychopathology, University of Groningen, Groningen, the Netherlands (Van den Hoofdakker); and the Donders Institute for Brain, Cognition, and Behavior and the Department of Cognitive Neuroscience, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands (Buitelaar)
| |
Collapse
|
4
|
Pagano ME, Delos-Reyes CM, Wasilow S, Svala KM, Kurtz SP. Smoking Cessation and Adolescent Treatment Response With Comorbid ADHD. J Subst Abuse Treat 2016; 70:21-27. [PMID: 27692184 DOI: 10.1016/j.jsat.2016.07.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2015] [Revised: 07/02/2016] [Accepted: 07/25/2016] [Indexed: 11/17/2022]
Abstract
Minors entering treatment for alcohol and other drug (AOD) use disorders tend to smoke at high rates, and many have comorbid attention deficit hyperactivity disorder (ADHD). Clear-air laws force patients to refrain from smoking on the premises of AOD treatment facilities, which may hinder the progress of treatment-seeking populations who smoke and struggle with ADHD comorbidity in particular. This study explores clinical characteristics associated with smoking among youths presenting for residential treatment, clinical characteristics associated with smoking cessation, and the impact of smoking cessation with ADHD comorbidity on AOD treatment response. Participants were 195 adolescents (52% female, aged 14-18 years) court-referred to residential treatment. Data were collected at intake, prospectively each week for the 10-week treatment period, and at discharge. Two-thirds (67%) of the enrollment sample entered treatment smoking half a pack a day on average, a large proportion (50%) of which did not smoke during treatment. ADHD patients were more likely to smoke before and during treatment except for those who got active in service and step-work. Quitting smoking did not adversely affect AOD outcomes and was associated with better prognosis of lowered AOD cravings for youths with and without ADHD. Smoking cessation during adolescent AOD treatment is recommended with provision of pharmaceutical and/or behavioral modalities that reduce nicotine withdrawal.
Collapse
Affiliation(s)
- Maria E Pagano
- Case Western Reserve University (CWRU), Department of Psychiatry, Cleveland, OH.
| | | | - Sherry Wasilow
- Carleton University, School of Journalism and Communication, Ottawa, ON
| | - Kathleen M Svala
- Case Western Reserve University (CWRU), Department of Psychiatry, Cleveland, OH
| | - Steven P Kurtz
- Center for Applied Research on Substance Use and Health Disparities, Department of Justice and Human Services, Nova Southeastern University, Miami, FL
| |
Collapse
|
5
|
Abstract
BACKGROUND Limited empirical investigation exists into longitudinal changes in cognition, behavior or quality of life (QOL) in children with perinatal HIV who are prescribed stimulants. METHODS This study was an analysis of longitudinal data from children age 3-19 years, with perinatal HIV infection, with and without prescriptions for stimulant medications [prescription (PG) and comparison (CG) groups, respectively], matched on age, availability of CD4% and outcome measures of cognition, behavior and QOL. Generalized estimating equation models were used to evaluate effects of stimulant exposure on change in measured outcomes over 3 years of follow-up, adjusting for baseline levels of outcomes and relevant covariates. RESULTS Children in both the PG (n = 132) and the CG (n = 392) obtained mean verbal and performance (nonverbal) intelligence quotients (VIQ and PIQ, respectively) in the low-average range for age. At baseline, those in PG demonstrated more frequent signs of hyperactivity, impulsivity and conduct and learning problems than those in CG (P ≤ 0.003 in unadjusted analyses). At follow-up, after adjustment for baseline functioning and other relevant covariates, there were no significant changes from baseline in VIQ or PIQ. Stimulant prescription use, however, was associated with worsening symptoms of hyperactivity (P = 0.01), impulsivity (P = 0.04), learning problems (P < 0.001) and worsening of perceived health status (P < 0.001). CONCLUSIONS The results suggest expectations for behavioral improvement may not align well with long-term effects of stimulant prescription use on behavior and QOL in children with HIV. Further research is necessary to determine if there are subsets of children who may benefit from stimulant therapy.
Collapse
|
6
|
Wagner DJ, McLennan JD. An Alternative Approach to Scoring the MTA-SNAP-IV to Guide Attention-Deficit/Hyperactivity Disorder Medication Treatment Titration towards Symptom Remission: A Preliminary Consideration. J Child Adolesc Psychopharmacol 2015; 25:749-53. [PMID: 26682996 DOI: 10.1089/cap.2015.0081] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
OBJECTIVE The Multimodal Treatment Study for Attention-Deficit/Hyperactivity Disorder Swanson, Nolan, and Pelham, Version IV (MTA-SNAP-IV) is a common rating scale to measure attention-deficit/hyperactivity disorder (ADHD) symptoms during medication treatment. Relying on the traditional scoring approach for this instrument to identify symptom remission, however, may leave a child with significant residual symptoms. The objective of this study was to examine an alternative scoring approach for this instrument to identify the extent of residual symptoms for children completing ADHD medication treatment. METHODS Parent and teacher ratings on the ADHD symptom component of the MTA-SNAP-IV were extracted from medical records of 80 children completing medication treatment at a specialty clinic in Canada. Data were scored in two ways. 1) Traditional scoring based on assigning a value ranging from 0 to 3 for response options: "Not at all," "Just a little," "Pretty much," or "Very much," for each symptom and then determining a mean across items, and 2) alternative scoring based on assigning values of 0, 0, 0.5, and 1 across the same response options and summing the total across items. Symptom remission based on the former is defined as a mean value ≤ 1, and for the latter it is defined as a summed value equal to 0. RESULTS Children were significantly less likely to be classified as symptom remitted under the alternative scoring method based on parent, teacher, and combined parent-teacher ratings. Using the alternative scoring approach, residual symptoms were identified for 25%, 39%, and 70% of children classified as symptom remitted (under traditional scoring rules) by parents, teachers, and parents/teachers combined, respectively. CONCLUSIONS Potential "residual" ADHD symptoms were identified in many children attaining symptom remission using the traditional scoring approach; however, further scrutiny of this alternative scoring approach is required. Although it may improve the ability to detect residual symptoms that could signal the need for further intervention to achieve symptom remission, it may increase the risk of over treatment.
Collapse
Affiliation(s)
- Daniel J Wagner
- 1 Institute of Health Policy, Management and Evaluation, University of Toronto , Toronto, Ontario, Canada
| | - John D McLennan
- 2 Department of Pediatrics, Psychiatry and Community Health Sciences, Cumming School of Medicine. University of Calgary , Calgary, Alberta, Canada
| |
Collapse
|
7
|
Coghill D, Seth S. Effective management of attention-deficit/hyperactivity disorder (ADHD) through structured re-assessment: the Dundee ADHD Clinical Care Pathway. Child Adolesc Psychiatry Ment Health 2015; 9:52. [PMID: 26587055 PMCID: PMC4652349 DOI: 10.1186/s13034-015-0083-2] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/02/2015] [Accepted: 09/30/2015] [Indexed: 12/17/2022] Open
Abstract
Attention-deficit/hyperactivity disorder (ADHD) has become a major aspect of the work of child and adolescent psychiatrists and paediatricians in the UK. In Scotland, Child and Adolescent Mental Health Services were required to address an increase in referral rates and changes in evidence-based medicine and guidelines without additional funding. In response to this, clinicians in Dundee have, over the past 15 years, pioneered the use of integrated psychiatric, paediatric, nursing, occupational therapy, dietetic and psychological care with the development of a clearly structured, evidence-based assessment and treatment pathway to provide effective therapy for children and adolescents with ADHD. The Dundee ADHD Clinical Care Pathway (DACCP) uses standard protocols for assessment, titration and routine monitoring of clinical care and treatment outcomes, with much of the clinical work being nurse led. The DACCP has received international attention and has been used as a template for service development in many countries. This review describes the four key stages of the clinical care pathway (referral and pre-assessment; assessment, diagnosis and treatment planning; initiating treatment; and continuing care) and discusses translation of the DACCP into other healthcare systems. Tools for healthcare professionals to use or adapt according to their own clinical settings are also provided.
Collapse
Affiliation(s)
- David Coghill
- Division of Neuroscience, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY UK
| | - Sarah Seth
- Division of Neuroscience, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY UK
| |
Collapse
|
8
|
Vallerand IA, Kalenchuk AL, McLennan JD. Behavioural treatment recommendations in clinical practice guidelines for attention-deficit/hyperactivity disorder: a scoping review. Child Adolesc Ment Health 2014; 19:251-258. [PMID: 32878350 DOI: 10.1111/camh.12062] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 02/12/2014] [Indexed: 11/29/2022]
Abstract
BACKGROUND The extent of behavioural treatment recommendations described in attention-deficit/hyperactivity disorder (ADHD) practice guidelines has not been examined. METHOD A scoping review identified eight agency-based ADHD practice guidelines. Key components of behavioural treatment recommendations were summarized. RESULTS All guidelines mentioned behavioural treatment as a consideration for managing ADHD, however, the extent to which they were detailed varied. Most guidelines provided lists of behavioural techniques but with minimal specifics regarding treatment delivery. CONCLUSIONS There is far less detailing of behavioural approaches compared to pharmacological treatments for ADHD. Greater detailing of evidence-based behavioural approaches may foster improved delivery of high-quality behaviour treatment.
Collapse
Affiliation(s)
- Isabelle A Vallerand
- Department of Community Health Sciences, Faculty of Medicine, University of Calgary, TRW Building, 3rd Floor, 3280 Hospital Drive NW, Calgary, AB, T2N 4Z6, Canada
| | - Anna L Kalenchuk
- Department of Psychiatry, British Columbia Children's Hospital, Vancouver, BC, Canada
| | - John D McLennan
- Departments of Pediatrics, Psychiatry & Community Health Sciences, Faculty of Medicine, University of Calgary, Calgary, AB, Canada
| |
Collapse
|
9
|
Wagner DJ, Vallerand IA, McLennan JD. Treatment receipt and outcomes from a clinic employing the attention-deficit/hyperactivity disorder treatment guideline of the children's medication algorithm project. J Child Adolesc Psychopharmacol 2014; 24:472-80. [PMID: 25329880 DOI: 10.1089/cap.2014.0014] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
OBJECTIVE Little is known about the pattern of service receipt and outcomes from clinics implementing best practice guidelines in child mental health. This study aimed to determine these variables for a clinic that implemented an attention-deficit/hyperactivity disorder (ADHD) treatment guideline proposed by the Children's Medication Algorithm Project (CMAP). METHODS Secondary analyses of medical record extracts were conducted for children who received treatment from 2007 to 2012 in a specialty clinic linked to a public children's hospital in Canada. Patterns of medication selection and dosing were compared with CMAP guidelines. Outcomes were based on parent and teacher ratings on the ADHD portion of the Multimodal Treatment Study for ADHD (MTA)- Swanson, Nolan, and Pelham, Version IV (SNAP-IV). RESULTS Data were available for 132 children (ages 5-14), 81.8% of whom had no previous ADHD medication exposure, and 97.0% of whom had started at least one medication. Methylphenidate was used first for 59.8% of children, whereas 33.3% started with an amphetamine product. Of the 47.0% of children who progressed to a second medication trial, 88.7% tried a stimulant from a second class. In total, 19.7% tried atomoxetine, which was typically used as a third stage choice (i.e., after two different stimulant exposures). Stage four to six medications were rarely used, rather stimulants were retried after atomoxetine and/or medication combinations were tried. Symptomatic remission at the end of treatment was achieved by 70.4% and 82.4%, according to parents and teachers respectively, for those with outcome data and who completed treatment. Outcomes for those further along the treatment algorithm were similar to discharges at the beginning of the algorithm. CONCLUSIONS The high rates of symptomatic remission observed within this clinical service may be a function of adherence to CMAP recommendations. However, the lack of a comparison group or experimental design prevents determination of causality. Additional investigations of the impacts of implementing evidence-based guidelines are critically needed, with proposed benchmarks to inform outcome evaluations.
Collapse
Affiliation(s)
- Daniel J Wagner
- 1 Faculty of Medicine, University of Calgary , Calgary, Alberta, Canada
| | | | | |
Collapse
|
10
|
Stein MA, Waldman ID, Charney E, Aryal S, Sable C, Gruber R, Newcorn JH. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adolesc Psychopharmacol 2011; 21:581-8. [PMID: 22136094 PMCID: PMC3243461 DOI: 10.1089/cap.2011.0018] [Citation(s) in RCA: 66] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE To compare the dose effects of long-acting extended-release dexmethylphenidate (ER d-MPH) and ER mixed amphetamine salts (ER MAS) on attention-deficit/hyperactivity disorder (ADHD) symptom dimensions, global and specific impairments, and common adverse events associated with stimulants. METHODS Fifty-six children and adolescents with ADHD participated in an 8-week, double-blind, crossover study comparing ER d-MPH (10, 20, 25-30 mg) and ER MAS (10, 20, 25-30) with a week of randomized placebo within each drug period. Efficacy was assessed with the ADHD Rating Scale-IV (ADHD-RS-IV), whereas global and specific domains of impairment were assessed with the Clinical Global Impressions Severity and Improvement Scales and the parent-completed Weiss Functional Impairment Scale, respectively. Insomnia and decreased appetite, common stimulant-related adverse events, were measured with the parent-completed Stimulant Side Effects Rating Scale. RESULTS Both ER d-MPH and ER MAS were associated with significant reductions in ADHD symptoms. Improvement in Total ADHD and Hyperactivity/Impulsivity symptoms were strongly associated with increasing dose, whereas improvements in Inattentive symptoms were only moderately associated with dose. About 80% demonstrated reliable change on ADHD-RS-IV at the highest dose level of ER MAS compared with 79% when receiving ER d-MPH. Decreased appetite and insomnia were more common at higher dose levels for both stimulants. Approximately 43% of the responders were preferential responders to only one of the stimulant formulations. CONCLUSIONS Dose level, rather than stimulant class, was strongly related to medication response.
Collapse
Affiliation(s)
- Mark A. Stein
- Institute for Juvenile Research, University of Illinois, Chicago, Illinois
| | | | - Elizabeth Charney
- Institute for Juvenile Research, University of Illinois, Chicago, Illinois
| | | | - Craig Sable
- Children's National Medical Center, Washington, District of Columbia
| | | | | |
Collapse
|
11
|
Lavigne JV, Dulcan MK, LeBailly SA, Binns HJ, Cummins TK, Jha P. Computer-assisted management of attention-deficit/hyperactivity disorder. Pediatrics 2011; 128:e46-53. [PMID: 21669891 PMCID: PMC3124100 DOI: 10.1542/peds.2010-2684] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/02/2011] [Indexed: 11/24/2022] Open
Abstract
OBJECTIVES Medication management of attention-deficit/hyperactivity disorder (ADHD) is often suboptimal. We examined whether (1) brief physician training plus computer-assisted medication management led to greater reduction in ADHD symptoms and (2) adherence to the recommended titration protocol produced greater symptomatic improvement. METHODS A randomized medication trial was conducted that included 24 pediatric practices. Children who met criteria for ADHD were randomly assigned by practice to treatment-as-usual or a specialized care group in which physicians received 2 hours of didactic training on medication management of ADHD plus training on a software program to assist in monitoring improvement. Parent and teacher reports were obtained before treatment and 4, 9, and 12 months after starting medication. RESULTS Children in both specialized care and treatment-as-usual groups improved on the ADHD Rating Scales and SNAP-IV, but there were no group differences in improvement rates. Brief physician training alone did not produce improvements. When recommended titration procedures were followed, however, outcomes were better for total and inattentive ADHD symptoms on both the ADHD Rating Scales and SNAP-IV parent and teacher scales. Results were not attributable to discontinuation because of adverse effects or failure to find an effective medication dose. CONCLUSIONS Brief physician training alone did not lead to reductions in ADHD symptoms, but adherence to a protocol that involved titration until the child's symptoms were in the average range and had shown a reliable change led to better symptom reduction. Computer-assisted medication management can contribute to better treatment outcomes in primary care medication treatment of ADHD.
Collapse
Affiliation(s)
- John V Lavigne
- Department of Child and Adolescent Psychiatry (#10), Children's Memorial Hospital, 2300 Children's Plaza, Chicago, IL 60614, USA.
| | | | | | | | | | | |
Collapse
|
12
|
Impact of medications prescribed for treatment of attention-deficit hyperactivity disorder on physical growth in children and adolescents with HIV. J Dev Behav Pediatr 2009; 30:403-12. [PMID: 19827220 PMCID: PMC2836888 DOI: 10.1097/dbp.0b013e3181ba0cf6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
OBJECTIVE To examine the relationships between physical growth and medications prescribed for symptoms of attention-deficit hyperactivity disorder in children with HIV. METHODS Analysis of data from children with perinatally acquired HIV (N = 2251; age 3-19 years), with and without prescriptions for stimulant and nonstimulant medications used to treat attention-deficit hyperactivity disorder, in a long-term observational study. Height and weight measurements were transformed to z scores and compared across medication groups. Changes in z scores during a 2-year interval were compared using multiple linear regression models adjusting for selected covariates. RESULTS Participants with (n = 215) and without (n = 2036) prescriptions were shorter than expected based on US age and gender norms (p < .001). Children without prescriptions weighed less at baseline than children in the general population (p < .001) but gained height and weight at a faster rate (p < .001). Children prescribed stimulants were similar to population norms in baseline weight; their height and weight growth velocities were comparable with the general population and children without prescriptions (for weight, p = .511 and .100, respectively). Children prescribed nonstimulants had the lowest baseline height but were similar to population norms in baseline weight. Their height and weight growth velocities were comparable with the general population but significantly slower than children without prescriptions (p = .01 and .02, respectively). CONCLUSION The use of stimulants to treat symptoms of attention-deficit hyperactivity disorder does not significantly exacerbate the potential for growth delay in children with HIV and may afford opportunities for interventions that promote physical growth. Prospective studies are needed to confirm these findings.
Collapse
|
13
|
Graham J, Coghill D. Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs 2008; 22:213-37. [PMID: 18278977 DOI: 10.2165/00023210-200822030-00003] [Citation(s) in RCA: 134] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Medication for the treatment of attention-deficit hyperactivity disorder (ADHD) is in widespread use globally. There is considerable data suggesting that overall, the adverse effect burden from this use is dose dependent and is in the mild to moderate category, but few comprehensive reviews exist of the epidemiology of adverse effects alone. This review provides a general and systems-specific summary of the scientific literature regarding adverse effect data for the drugs in general use for the treatment of ADHD. Although several areas lack definitive data, current evidence suggests that, for the majority of those treated for ADHD, the medications currently available pose little in the way of risk of significant harm. Epidemiological data suggest a low incidence of serious adverse effects, whilst the less serious adverse effects, such as insomnia and anorexia, are relatively common. Also, some specific areas of study suggest lower risks of harm than previously thought, e.g. tic disorders and seizures. However, pre-existing conditions and other interindividual differences may raise the risk of harmful adverse effects, which adds emphasis to the need for careful pretreatment assessment and monitoring. Potential but unlikely long-term treatment effects need to be investigated as carefully as possible, particularly with regard to cardiac sequelae and carcinogenesis. There are both overlaps and differences between the adverse effects of stimulants and nonstimulants, such as atomoxetine. For example, the latter shares the stimulant group's potential for changing cardiovascular parameters, but may not cause insomnia.
Collapse
Affiliation(s)
- Johnny Graham
- Child and Adolescent Psychiatry, University of Dundee, Section of Psychiatry, Division of Pathology and Neuroscience, Ninewells Hospital, Dundee, Scotland.
| | | |
Collapse
|
14
|
Szobot CM, Rohde LA, Bukstein O, Molina BSG, Martins C, Ruaro P, Pechansky F. Is attention-deficit/hyperactivity disorder associated with illicit substance use disorders in male adolescents? A community-based case-control study. Addiction 2007; 102:1122-30. [PMID: 17567400 DOI: 10.1111/j.1360-0443.2007.01850.x] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
AIMS This study aims at evaluating the association between attention-deficit/hyperactivity disorder (ADHD) and illicit substance use disorders (SUD) (marijuana, cocaine and inhalants), controlling for the association with conduct disorder (CD), in a community-based sample of adolescents. DESIGN Case-control, community-based study. SETTING A delimited geographical area in the South of Brazil, served by four public health clinics. PARTICIPANTS A total of 968 male adolescents (15-20 years of age) were screened for SUD in their households. Of the subjects who were screened positive, we selected 61 cases with illicit SUD. For each case we selected, from the group which was screened negative, three controls without illicit or alcohol SUD, matched by age and proximity with the case's household. MEASUREMENTS The screening instrument was the Alcohol Smoking and Substance Screening Test (ASSIST). SUD diagnoses were assessed by the drug section of the Mini International Neuropsychiatry Interview (MINI). Other psychiatric diagnoses were based on semistructured (Schedule for Affective Disorders and Schizophrenia for School-Age Children-epidemiological version; MINI) and clinical interviews. FINDINGS Adolescents with ADHD presented a significantly higher odds ratio (OR) for illicit SUD than youths without ADHD, even after adjusting for potential confounders (CD, ethnicity, religion and estimated IQ) (OR = 9.12; 95% CI = 2.84-29.31, P < 0.01). CONCLUSIONS Our results suggest an association between ADHD and illicit SUD in Brazilian adolescents that is not mediated by CD. These findings are potentially important from a prevention perspective because treatments are available for ADHD.
Collapse
Affiliation(s)
- Claudia M Szobot
- Center for Drug and Alcohol Research, Hospital de Clínicas de Porto Alegre, Federal University of Rio Grande do Sul, Brazil.
| | | | | | | | | | | | | |
Collapse
|
15
|
Abstract
Approximately one-half of children medicated for attention-deficit hyperactivity disorder (ADHD) will continue to experience sufficient impairment during adolescence to warrant the continuation of their treatment; a smaller number of people with ADHD may require treatment for the first time during adolescence. The academic and social demands of adolescence can exaggerate the impairment caused by attentional problems, as adolescents, more so than children, have activities in the afternoon and evening that will tax their attentional abilities. Stimulant and nonstimulant medications are likely to be as effective for adolescent patients as they are for younger children, provided treatment adherence is satisfactory. Long-acting medications are preferred over immediate-release compounds as they provide better coverage of symptoms throughout the day. Patterns of comorbidity with ADHD change from childhood to adolescence and may require a shift in treatment strategy. The choice of time to discontinue treatment should be a decision shared by the clinician and the patient. A negotiated trial of time off treatment followed by a review of the patient's symptoms can avert premature discontinuation of treatment.
Collapse
Affiliation(s)
- Philip Hazell
- Thomas Walker Hospital (Rivendell) Child, Adolescent and Family Mental Health Service, Concord West, New South Wales, Australia.
| |
Collapse
|
16
|
Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, McCRACKEN JT, Swanson JM, Lopez M. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45:642-657. [PMID: 16721314 DOI: 10.1097/01.chi.0000215326.51175.eb] [Citation(s) in RCA: 251] [Impact Index Per Article: 13.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE In 1998, the Texas Department of Mental Health and Mental Retardation developed algorithms for medication treatment of attention-deficit/hyperactivity disorder (ADHD). Advances in the psychopharmacology of ADHD and results of a feasibility study of algorithm use in community mental health centers caused the algorithm to be modified and updated. METHOD We convened a consensus conference of academic clinicians and researchers, practicing clinicians, administrators, consumers, and families to revise the algorithms for the pharmacotherapy of ADHD itself as well as ADHD with specific comorbid disorders. New research was reviewed by national experts, and rationales were provided for proposed changes and additions to the algorithms. The changes to the algorithms were discussed and approved both by the national experts and experienced clinicians from the Texas public mental health system. RESULTS The panel developed consensually agreed-upon algorithms for ADHD with and without comorbid disorders. The major changes included elimination of pemoline as a treatment option, adding atomoxetine to the algorithm, and refining guidelines for treating ADHD with comorbid depression, aggressive behaviors, and tic disorders. CONCLUSIONS Medication algorithms for ADHD can be modified to keep abreast of developments in the field. Although these evidence- and consensus-based treatment recommendations may be a useful approach to guide the treatment of ADHD in children, additional research is needed to determine how these algorithms can be used to maximally benefit child outcomes.
Collapse
Affiliation(s)
- Steven R Pliszka
- Dr. Pliszka is with the Department of Psychiatry, University of Texas Health Science Center at San Antonio; Dr. Crismon is with the College of Pharmacy, University of Texas at Austin; Dr. Hughes is with the Department of Psychology and Dr. Emslie is with the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas; Dr. Conners is with the Department of Psychiatric & Behavioral Science, Duke University, Durham, NC; Dr. Jensen is with Columbia University, New York State Psychiatric Institute, New York; Dr. McCracken is with the UCLA Neuropsychiatric Institute, Los Angeles; Dr. Swanson is with the Department of Psychiatry, University of California at Irvine; and Dr. Lopez is with the Texas Department of State Health Services, Austin.
| | - M Lynn Crismon
- Dr. Pliszka is with the Department of Psychiatry, University of Texas Health Science Center at San Antonio; Dr. Crismon is with the College of Pharmacy, University of Texas at Austin; Dr. Hughes is with the Department of Psychology and Dr. Emslie is with the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas; Dr. Conners is with the Department of Psychiatric & Behavioral Science, Duke University, Durham, NC; Dr. Jensen is with Columbia University, New York State Psychiatric Institute, New York; Dr. McCracken is with the UCLA Neuropsychiatric Institute, Los Angeles; Dr. Swanson is with the Department of Psychiatry, University of California at Irvine; and Dr. Lopez is with the Texas Department of State Health Services, Austin
| | - Carroll W Hughes
- Dr. Pliszka is with the Department of Psychiatry, University of Texas Health Science Center at San Antonio; Dr. Crismon is with the College of Pharmacy, University of Texas at Austin; Dr. Hughes is with the Department of Psychology and Dr. Emslie is with the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas; Dr. Conners is with the Department of Psychiatric & Behavioral Science, Duke University, Durham, NC; Dr. Jensen is with Columbia University, New York State Psychiatric Institute, New York; Dr. McCracken is with the UCLA Neuropsychiatric Institute, Los Angeles; Dr. Swanson is with the Department of Psychiatry, University of California at Irvine; and Dr. Lopez is with the Texas Department of State Health Services, Austin
| | - C Keith Corners
- Dr. Pliszka is with the Department of Psychiatry, University of Texas Health Science Center at San Antonio; Dr. Crismon is with the College of Pharmacy, University of Texas at Austin; Dr. Hughes is with the Department of Psychology and Dr. Emslie is with the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas; Dr. Conners is with the Department of Psychiatric & Behavioral Science, Duke University, Durham, NC; Dr. Jensen is with Columbia University, New York State Psychiatric Institute, New York; Dr. McCracken is with the UCLA Neuropsychiatric Institute, Los Angeles; Dr. Swanson is with the Department of Psychiatry, University of California at Irvine; and Dr. Lopez is with the Texas Department of State Health Services, Austin
| | - Graham J Emslie
- Dr. Pliszka is with the Department of Psychiatry, University of Texas Health Science Center at San Antonio; Dr. Crismon is with the College of Pharmacy, University of Texas at Austin; Dr. Hughes is with the Department of Psychology and Dr. Emslie is with the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas; Dr. Conners is with the Department of Psychiatric & Behavioral Science, Duke University, Durham, NC; Dr. Jensen is with Columbia University, New York State Psychiatric Institute, New York; Dr. McCracken is with the UCLA Neuropsychiatric Institute, Los Angeles; Dr. Swanson is with the Department of Psychiatry, University of California at Irvine; and Dr. Lopez is with the Texas Department of State Health Services, Austin
| | - Peter S Jensen
- Dr. Pliszka is with the Department of Psychiatry, University of Texas Health Science Center at San Antonio; Dr. Crismon is with the College of Pharmacy, University of Texas at Austin; Dr. Hughes is with the Department of Psychology and Dr. Emslie is with the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas; Dr. Conners is with the Department of Psychiatric & Behavioral Science, Duke University, Durham, NC; Dr. Jensen is with Columbia University, New York State Psychiatric Institute, New York; Dr. McCracken is with the UCLA Neuropsychiatric Institute, Los Angeles; Dr. Swanson is with the Department of Psychiatry, University of California at Irvine; and Dr. Lopez is with the Texas Department of State Health Services, Austin
| | - James T McCRACKEN
- Dr. Pliszka is with the Department of Psychiatry, University of Texas Health Science Center at San Antonio; Dr. Crismon is with the College of Pharmacy, University of Texas at Austin; Dr. Hughes is with the Department of Psychology and Dr. Emslie is with the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas; Dr. Conners is with the Department of Psychiatric & Behavioral Science, Duke University, Durham, NC; Dr. Jensen is with Columbia University, New York State Psychiatric Institute, New York; Dr. McCracken is with the UCLA Neuropsychiatric Institute, Los Angeles; Dr. Swanson is with the Department of Psychiatry, University of California at Irvine; and Dr. Lopez is with the Texas Department of State Health Services, Austin
| | - James M Swanson
- Dr. Pliszka is with the Department of Psychiatry, University of Texas Health Science Center at San Antonio; Dr. Crismon is with the College of Pharmacy, University of Texas at Austin; Dr. Hughes is with the Department of Psychology and Dr. Emslie is with the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas; Dr. Conners is with the Department of Psychiatric & Behavioral Science, Duke University, Durham, NC; Dr. Jensen is with Columbia University, New York State Psychiatric Institute, New York; Dr. McCracken is with the UCLA Neuropsychiatric Institute, Los Angeles; Dr. Swanson is with the Department of Psychiatry, University of California at Irvine; and Dr. Lopez is with the Texas Department of State Health Services, Austin
| | - Molly Lopez
- Dr. Pliszka is with the Department of Psychiatry, University of Texas Health Science Center at San Antonio; Dr. Crismon is with the College of Pharmacy, University of Texas at Austin; Dr. Hughes is with the Department of Psychology and Dr. Emslie is with the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas; Dr. Conners is with the Department of Psychiatric & Behavioral Science, Duke University, Durham, NC; Dr. Jensen is with Columbia University, New York State Psychiatric Institute, New York; Dr. McCracken is with the UCLA Neuropsychiatric Institute, Los Angeles; Dr. Swanson is with the Department of Psychiatry, University of California at Irvine; and Dr. Lopez is with the Texas Department of State Health Services, Austin
| |
Collapse
|
17
|
Affiliation(s)
- Susan Denisco
- Family Nurse Practitioner Program at Sacred Heart University, Fairfield, CT, USA
| | | | | |
Collapse
|
18
|
Dopheide JA. ASHP Therapeutic Position Statement on the Appropriate Use of Medications in the Treatment of Attention-Deficit/Hyperactivity Disorder in Pediatric Patients. Am J Health Syst Pharm 2005; 62:1502-9. [PMID: 15998933 DOI: 10.2146/ajhp040600] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Affiliation(s)
- Julie A Dopheide
- Schools of Pharmacy and Medicine, University of Southern California, 1985 Zonal Avenue, Los Angeles, CA 90089, USA.
| |
Collapse
|
19
|
Abstract
A Global ADHD Working Group of experienced clinicians and researchers was gathered to review the latest evidence, discuss current best practice in the treatment of attention-deficit/hyperactivity disorder (ADHD), and make a statement based on consensus. The statement aims to re-affirm ADHD as a valid disorder that exists across different cultures, has a significant global impact, and should be diagnosed and effectively treated wherever it occurs. ADHD is one of the most common neurobehavioural disorders of childhood and impacts on many aspects of development, including social, emotional and cognitive functioning, in the home and school environment. Although these findings are from developed countries, the impact in developing countries is likely to be similar. There is strong supportive evidence for the validity of ADHD as a syndrome with neurobiological aspects, and complex genetic factors are primarily implicated in the aetiology. Accurate diagnosis and measurement of impairment is important to enable appropriate and successful management of symptoms. ADHD is a persistent condition that needs to be treated and monitored over time. The evidence supporting medication-based interventions (such as methylphenidate) is strong and consensus treatment algorithms to guide the multimodal treatment of ADHD, alone and in combination with common comorbidities, are suggested.
Collapse
Affiliation(s)
- Helmut Remschmidt
- Klinik für Kinder- und Jugendpsychiatrie und Psychotherapie, Universität Marburg, Hans-Sachs-Str. 4-6, 35033 Marburg, Germany.
| |
Collapse
|
20
|
Sevecke K, Döpfner M, Lehmkuhl G. Die Wirksamkeit von Stimulanzien-Retardpräparaten bei Kindern und Jugendlichen mit ADHD - eine systematische Übersicht. ZEITSCHRIFT FUR KINDER-UND JUGENDPSYCHIATRIE UND PSYCHOTHERAPIE 2004; 32:265-78. [PMID: 15565896 DOI: 10.1024/1422-4917.32.4.265] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Zusammenfassung: Stimulanzien sind das Mittel der Wahl zur pharmakologischen Behandlung einer Aufmerksamkeits-/Hyperaktivitätsstörung. Jedoch ist die Wirkdauer von schnell freisetzenden Präparaten oft nicht ausreichend. Mittlerweile wurden verschiedene retardierte Methylphenidat-, aber auch Amphetaminformen entwickelt, um die Probleme einer mehrfach täglichen Einnahme zu minimieren. Der Artikel stellt die klinischen Studien zu Wirksamkeit, Wirkdauer und Nebenwirkungsprofil verschiedener Stimulanzienformen dar. In der klinischen Anwendung sind die neuen Retard-Produkte wirkungsvolle Alternativen. Eine kontinuierliche mehrstufige Freisetzung des Wirkstoffs über den Tag verteilt nach einmaliger Medikamentengabe bietet Vorteile. Allerdings müssen Nebenwirkungen durch die verlängerte Wirkungsdauer genau beobachtet werden. Eine genauere Anpassung an die jeweiligen Erfordernisse der verschiedenen Tagesabschnitte und -bedürfnisse der Kinder und Jugendlichen ist schwierig. Die Erprobung von Titrierungsschemata unter Einbeziehung von schnell und verzögert freisetzenden Präparaten bleibt eine Aufgabe zukünftiger Forschung.
Collapse
Affiliation(s)
- Kathrin Sevecke
- Klinik und Poliklinik for Psychiatrie und Psychotherapie des Kindes- und Jugendalters am Klinikum der Universität zu Köln
| | | | | |
Collapse
|
21
|
Sinzig JK, Döpfner M, Plück J, Banaschewski T, Stephani U, Lehmkuhl G, Rothenberger A. Lassen sich hyperkinetische Auffälligkeiten am Nachmittag durch eine Morgengabe von Methylphenidat Retard vermindern? ZEITSCHRIFT FUR KINDER-UND JUGENDPSYCHIATRIE UND PSYCHOTHERAPIE 2004; 32:225-33. [PMID: 15565893 DOI: 10.1024/1422-4917.32.4.225] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Zusammenfassung: Fragestellung: Neuere galenische Zubereitungen erlauben es, langzeitwirksame Methylphenidatpräparate mit einer zweistufigen Freisetzungsdynamik herzustellen und so durch eine morgendliche Einmalgabe der Unterstützung von Schulkindern mit Aufmerksamkeitsdefizit-/Hyperaktitivätsstörung (ADHS) besser gerecht zu werden. Die Studie analysiert die Wirksamkeit von Medikinet®-Retard, einem neuen retardierten Methylphenidat-Präparat, bei der Veränderung der ADHS-Symptomatik am Nachmittag nach Einschätzung der Lehrer und Eltern. An dieser Stelle soll insbesondere auf Effekte im Urteil der Eltern eingegangen werden. Methode: In einer placebo-kontrollierten, randomisierten, doppelblinden, multizentrischen Studie wurden 85 durchschnittlich intelligente Kinder (Alter 6-16 Jahre, Diagnose: ADHS) untersucht. Die Dauer der Behandlung mit Medikinet®-Retard (n = 43) bzw. Placebo (n = 42) betrug 4 Wochen mit wöchentlichen Visiten. Eine wöchentliche Titrierung erfolgte bis maximal 60 mg in Abhängigkeit vom Körpergewicht und dem Verlauf der Symptomatik. Kriterium für die Verminderung der Symptomatik in der Familie war die wöchentliche Einschätzung der Lehrer und Eltern im Fremdbeurteilungsbogen für Hyperkinetische Störungen (FBB-HKS). Ergebnisse: In der ADHS-Symptomatik, erfasst über den FBB-HKS, ließen sich signifikante Medikamentenwirkungen nachweisen. Die Effektstärke der Veränderungen lag bei d = 1.2 (Gesamtkennwert). Die Effekte ließen sich für Aufmerksamkeitsstörung, Hyperaktivität und Impulsivität auf den entsprechenden Subskalen belegen. Die Wirksamkeit von Medikinet®-Retard wurde von den Eltern durchschnittlich als gut eingeschätzt. Die Reponderrate war in der Verumgruppe viermal höher. Die Korrelationen der Veränderungswerte im Elternurteil mit den Veränderungswerten im Lehrerurteil lagen im mittleren Bereich. Schlussfolgerung: Mit dieser Studie liegen im deutschsprachigen Raum erstmals Daten für eine erfolgreiche Symptomreduktion und gute Wirksamkeit im Elternurteil eines langzeitwirksamen Methylphenidatpräparates (Medikinet®-Retard) vor. Die zweistufige Freisetzungsdynamik erlaubt eine praxistaugliche morgendliche Einmalgabe. Es zeigen sich Wirkungen bis in den Nachmittag.
Collapse
Affiliation(s)
- Judith K Sinzig
- Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters am Klinikum der Universität Köln
| | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
Youths with attention deficit hyperactivity disorder often experience weight loss on stimulants, which may limit optimal dosing and compliance. Cyproheptadine has been shown in medical samples to stimulate weight gain. We conducted a retrospective chart review of 28 consecutive pediatric psychiatry outpatients prescribed cyproheptadine for weight loss or insomnia while on stimulants. Of these, 4 patients never took cyproheptadine consistently, and 3 discontinued it within the first 7 days due to intolerable side effects. Data were analyzed for 21 other patients (age range 4-15 years) who continued with 4-8 mg of cyproheptadine nightly (mean final dose = 4.9 mg/day) for at least 14 days (mean duration = 104.7 days). Most had lost weight on stimulant alone (mean weight loss was 2.1 kg, mean weight velocity was -19.3 g/day). All 21 gained weight taking concomitant cyproheptadine, with a mean gain of 2.2 kg (paired t = 6.87, p < 0.0001) and a mean weight velocity of 32.3 g/day. Eleven of 17 patients who had reported initial insomnia on stimulant alone noted significant improvements in sleep with cyproheptadine added. We conclude that concomitant cyproheptadine may be useful in youths with attention deficit hyperactivity disorder for stimulant-induced weight loss, pending future randomized controlled trials.
Collapse
Affiliation(s)
- W Burleson Daviss
- Department of Psychiatry, Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, USA
| | | |
Collapse
|
23
|
Donnelly M, Haby MM, Carter R, Andrews G, Vos T. Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder. Aust N Z J Psychiatry 2004; 38:592-601. [PMID: 15298581 DOI: 10.1080/j.1440-1614.2004.01422.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
OBJECTIVE To analyze from a health sector perspective the cost-effectiveness of dexamphetamine (DEX) and methylphenidate (MPH) interventions to treat childhood attention deficit hyperactivity disorder (ADHD), compared to current practice. METHOD Children eligible for the interventions are those aged between 4 and 17 years in 2000, who had ADHD and were seeking care for emotional or behavioural problems, but were not receiving stimulant medication. To determine health benefit, a meta-analysis of randomized controlled trials was performed for DEX and MPH, and the effect sizes were translated into utility values. An assessment on second stage filter criteria ("equity", "strength of evidence", "feasibility" and "acceptability to stakeholders") is also undertaken to incorporate additional factors that impact on resource allocation decisions. Simulation modelling techniques are used to present a 95% uncertainty interval (UI) around the incremental cost-effectiveness ratio (ICER), which is calculated in cost (in A$) per DALY averted. RESULTS The ICER for DEX is A$4100/DALY saved (95% UI: negative to A$14 000) and for MPH is A$15 000/DALY saved (95% UI: A$9100-22 000). DEX is more costly than MPH for the government, but much less costly for the patient. CONCLUSIONS MPH and DEX are cost-effective interventions for childhood ADHD. DEX is more cost-effective than MPH, although if MPH were listed at a lower price on the Pharmaceutical Benefits Scheme it would become more cost-effective. Increased uptake of stimulants for ADHD would require policy change. However, the medication of children and wider availability of stimulants may concern parents and the community.
Collapse
Affiliation(s)
- Marie Donnelly
- Health Surveillance and Evaluation Section, Public Health, Department of Human Services, Melbourne, Australia
| | | | | | | | | |
Collapse
|
24
|
Bhatara V, Feil M, Hoagwood K, Vitiello B, Zima B. National trends in concomitant psychotropic medication with stimulants in pediatric visits: practice versus knowledge. J Atten Disord 2004; 7:217-26. [PMID: 15487478 DOI: 10.1177/108705470400700404] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
OBJECTIVES (1) To examine U.S. national trends in the use of concomitant pharmacotherapy with the stimulant class of psychotropic drugs in youth; and (2) to present these trends in the context of (a) extant safety and efficacy data, and (b) overall trends in concomitant pharmacotherapy with psychotropic drugs for youth. METHODS Prescribing data for youths under age 18 years from National Ambulatory Medical Surveys from 1993 to 1998 were analyzed. The visits were categorized into monotherapy (only one psychotropic prescribed) and concomitant pharmacotherapy (>1 psychotropic prescribed). The proportions of these groups were computed as a percentage of all visits during which a psychotropic medication was prescribed. Differences in proportions between surveys were analyzed to determine trends. RESULTS Between 1993--94 and 1997--98, the proportions of visits for concomitant pharmacotherapy in association with the stimulant class increased nearly five-fold. This increase paralleled an overall increase in the proportion of visits involving prescription of more than one psychotropic medication among youth. CONCLUSIONS The growth in concomitant pharmacotherapy with the stimulants class has out-paced the increase in safety/efficacy data to inform the use of this practice, resulting in a mismatch between trends in prescribing and growth in knowledge. A simultaneous trend of note is the overall increase in the use of concomitant pharmacotherapy with all psychotropic drugs in youth. Controlled trials are particularly needed to support commonly used combinations of stimulants with antidepressants in youth. In the absence of definitive data, clinical guidelines based on expert consensus and limited data are available and are useful.
Collapse
Affiliation(s)
- Vinod Bhatara
- University of South Dakota, Psychiatry and Family Medicine, USA.
| | | | | | | | | |
Collapse
|
25
|
Emslie GJ, Hughes CW, Crismon ML, Lopez M, Pliszka S, Toprac MG, Boemer C. A feasibility study of the childhood depression medication algorithm: the Texas Children's Medication Algorithm Project (CMAP). J Am Acad Child Adolesc Psychiatry 2004; 43:519-27. [PMID: 15100558 DOI: 10.1097/00004583-200405000-00005] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVE To evaluate the feasibility and impact on clinical response and function associated with the use of an algorithm-driven disease management program (ALGO) for children and adolescents treated for depression with or without attention-deficit/hyperactivity disorder (ADHD) in community mental health centers. METHOD Interventions included (1). medication algorithms, (2). clinical and technical support for the physician, (3). uniform chart documentation of outcomes, and (4). a patient/family psychoeducation program. Children eligible for entry into the study were referred to the child psychiatrist for initiation or change in medicine. Outcomes of treatment with the ALGO for up to 4 months are presented. Measures of change included clinical symptoms, functioning, and global improvement (Clinical Global Impression Scale). A historical chart cohort from the same clinics was used as a quasi-control. RESULTS Thirty-nine individuals (depression = 24; comorbid depression with ADHD = 15) were enrolled for treatment with ALGO. One hundred fourteen children were in the control cohort (74 depressed, 40 comorbid). For the ALGO groups, Children's Depression Rating Scale-Revised depression severity scores decreased from 48.2 to 32.5 and Child Adolescent Functioning Assessment Scale function scores improved from 70.3 to 40.9 (all p < or =.0005). Clinical Global Impression Scale severity scores decreased from 5.7 to 3.7 in ALGO compared to only 5.8 to 4.8 in the control (p <.003). CONCLUSIONS There was clear improvement in clinical symptoms, functioning, and global response with ALGO treatment. The magnitude of the improvement was greater in children and adolescents treated with the ALGO program compared with a historical cohort. These data support the need for controlled studies in larger populations examining the effects of algorithm-driven disease management programs on the clinical outcomes of children with mental illness.
Collapse
Affiliation(s)
- Graham J Emslie
- University of Texas Southwestern Medical Center-Dallas, TX 75390-8589, USA.
| | | | | | | | | | | | | |
Collapse
|
26
|
Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2004; 24:24-9. [PMID: 14709943 DOI: 10.1097/01.jcp.0000108984.11879.95] [Citation(s) in RCA: 274] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
This article reviews the efficacy of methylphenidate (MPH) for adult attention-deficit/hyperactivity disorder (ADHD). A literature search identified double-blind placebo-controlled MPH treatment studies of ADHD adults. Meta-analysis estimated the pooled effect size for MPH treatment and tested for publication bias. Meta-analysis regression assessed the influence of study design features on medication effects. Six trials met criteria and were included in this meta-analysis. These studies included a total of 140 MPH-treated ADHD adults and 113 placebo-treated ADHD adults. The mean effect size of 0.9 was statistically significant and there was no evidence of publication bias. Larger MPH effect sizes were associated with physician ratings of outcome and use of higher doses. When treatment is optimized to high doses, the effect size for MPH in adults was 1.3. We found strong support for the assertion that MPH is efficacious for treating adult ADHD. Because the degree of efficacy of MPH in treating ADHD adults is similar to what has been reported from meta-analyses of the child and adolescent literature, our work provides further assurance to clinicians that the diagnosis of ADHD can be validly applied in adulthood.
Collapse
Affiliation(s)
- Stephen V Faraone
- Pediatric Psychopharmacology Unit, Child Psychiatry Service, Massachusetts General Hospital, Boston, MA 02114-3139, USA.
| | | | | | | | | |
Collapse
|
27
|
Chu S. Attention deficit hyperactivity disorder (ADHD) part two: evaluation and intervention. ACTA ACUST UNITED AC 2003. [DOI: 10.12968/bjtr.2003.10.6.13534] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Sidney Chu
- Ealing Primary Care Trust, Windmill Lodge, Southall, Middlesex UB1 3EU UK
| |
Collapse
|
28
|
Greenhill L, Beyer DH, Finkleson J, Shaffer D, Biederman J, Conners CK, Gillberg C, Huss M, Jensen P, Kennedy JL, Klein R, Rapoport J, Sagvolden T, Spencer T, Swanson JM, Volkow N. Guidelines and algorithms for the use of methylphenidate in children with Attention-Deficit/ Hyperactivity Disorder. J Atten Disord 2003; 6 Suppl 1:S89-100. [PMID: 12685523 DOI: 10.1177/070674370200601s11] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE To review published algorithms for guiding the use of methylphenidate (MPH) in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents. METHODS A consensus roundtable of 12 experts was convened to review the evidence for the safety and efficacy of MPH in the treatment of ADHD, as well as the published algorithms and practice guidelines for using MPH. The experts reviewed the algorithms for practicality and acceptability by clinicians. RESULTS Algorithms that included MPH commonly selected it as the initial medication to be employed in the treatment of children with ADHD. Factors involved included its high efficacy, good safety record, and the ubiquitous nature of its appearance in the ADHD treatment literature. CONCLUSIONS MPH should be considered as the first medication to be used in a treatment algorithm for children and adolescents with ADHD.
Collapse
Affiliation(s)
- L Greenhill
- New York State Psychiatric Institute/Columbia University, New York 10032, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Abstract
Stimulants are a highly efficacious and safe treatment for attention-deficit/hyperactivity disorder (ADHD), with 75% to 90% of patients responding well if two different stimulants (amphetamine and methylphenidate) are used. Nonetheless, a subset of ADHD patients will either fail to respond to stimulants or have side effects that preclude their use (tics, severe loss of appetite, marked insomnia). For such patients, there are a number of non-stimulant agents that serve as second-line treatments. Tricyclic antidepressants (TCAs) are the most studied of these drugs. They are superior to placebo in the treatment of ADHD and may reduce abnormal movements in patients with ADHD/tic disorder. TCAs often produce side effects of sedation, dry mouth, and constipation. Bupropion is superior to placebo in the treatment of ADHD and has a more favorable side-effect profile than the TCAs. A new selective norepinephrine reuptake inhibitor, atomoxetine, has been shown to be efficacious in the treatment of ADHD and has recently received an approvable letter from the Food and Drug Administration. The a-agonists clonidine and guanfacine have also been used as alternative agents in ADHD, though the controlled data are more limited. A recent controlled clinical trial suggests a combination of methylphenidate and clonidine has advantages in the treatment of comorbid ADHD and tics over either medication alone. Clinical guidelines for each of these agents, as well as their use in combination with stimulants in comorbid conditions, will be discussed.
Collapse
Affiliation(s)
- Steven R Pliszka
- Department of Psychiatry, University of Texas Health Science Center, San Antonio 78284, USA.
| |
Collapse
|
30
|
Pliszka SR, Lopez M, Crismon ML, Toprac MG, Hughes CW, Emslie GJ, Boemer C. A feasibility study of the children's medication algorithm project (CMAP) algorithm for the treatment of ADHD. J Am Acad Child Adolesc Psychiatry 2003; 42:279-87. [PMID: 12595780 DOI: 10.1097/00004583-200303000-00007] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE To determine whether an algorithm for the treatment of attention-deficit/hyperactivity disorder (ADHD) can be implemented in a community mental health center. METHOD Fifty child and adolescent patients at Texas community mental health centers who met criteria for ADHD were treated according to an algorithm-based disease management program for ADHD. Psychiatrists were trained in the use of the algorithm, and each subject underwent a baseline assessment consisting of a structured interview and standardized rating scales. Subjects were monitored for 4 months. At the end of treatment, the psychiatrists completed the Clinical Global Impression Scale (CGI) and the baseline rating scales were repeated. The primary variables of interest were psychiatrist and family adherence to the algorithm. To examine impact on treatment outcome, the CGI of the algorithm subjects was compared with CGIs based on chart reviews of 118 historical controls. RESULTS Psychiatrists implemented the major aspects of the algorithm, but the detailed tactics of the algorithm (use of fixed titration of stimulants) were less well adhered to. CONCLUSIONS An algorithm for the treatment of ADHD can be implemented in a community mental health center.
Collapse
Affiliation(s)
- Steven R Pliszka
- University of Texas Health Science Center at San Antonio, Texas 8229-3900, USA.
| | | | | | | | | | | | | |
Collapse
|
31
|
Cala S, Crismon ML, Baumgartner J. A survey of herbal use in children with attention-deficit-hyperactivity disorder or depression. Pharmacotherapy 2003; 23:222-30. [PMID: 12587812 DOI: 10.1592/phco.23.2.222.32092] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVE To examine whether herbal medicines were given to children or adolescents receiving care for attention-deficit-hyperactivity disorder or depression. METHODS Between October 2000 and July 2001, a 23-item questionnaire was administered in five community mental health centers in Texas. Parents or primary caregivers of children who received a psychiatric assessment were sought for participation. One hundred seventeen caregivers completed a questionnaire. The main outcome measure was primary caregivers' self-report of the use of herbal therapy in their children. RESULTS The lifetime prevalence of herbal therapy in patients was 20% (23 patients). Eighteen patients (15%) had taken herbal medicines during the past year. Recommendations from a friend or relative resulted in the administration of herbal medicines by 61% of 23 caregivers. Herbal medicines were given most frequently for a behavioral condition, with ginkgo biloba, echinacea, and St. John's wort most prevalent. Almost 83% of caregivers gave herbal medicines alone, whereas 13% gave herbal medicines with prescription drugs. Most caregivers (78%) supervised the administration of herbal therapy in their children; the children's psychiatrists (70%), pediatricians (56%), or pharmacists (74%) typically were not aware of the use. CONCLUSIONS Most caregivers supervised herbal therapy in their children, without communication with a health professional. A need exists for better communication between health professionals and caregivers regarding the use of herbal therapy.
Collapse
|
32
|
Pappadopulos E, Macintyre Ii JC, Crismon ML, Findling RL, Malone RP, Derivan A, Schooler N, Sikich L, Greenhill L, Schur SB, Felton CJ, Kranzler H, Rube DM, Sverd J, Finnerty M, Ketner S, Siennick SE, Jensen PS. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. J Am Acad Child Adolesc Psychiatry 2003; 42:145-61. [PMID: 12544174 DOI: 10.1097/00004583-200302000-00008] [Citation(s) in RCA: 191] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE To develop treatment recommendations for the use of antipsychotic medications for children and adolescents with serious psychiatric disorders and externalizing behavior problems. METHOD Using a combination of evidence- and consensus-based methodologies, recommendations were developed in six phases as informed by three primary sources of information: (1) current scientific evidence (published and unpublished), (2) the expressed needs for treatment-relevant information and guidance specified by clinicians in a series of focus groups, and (3) consensus of clinical and research experts derived from a formal survey and a consensus workshop. RESULTS Fourteen treatment recommendations on the use of atypical antipsychotics for aggression in youth with comorbid psychiatric conditions were developed. Each recommendation corresponds to one of the phases of care (evaluation, treatment, stabilization, and maintenance) and includes a brief clinical rationale that draws upon the available scientific evidence and consensus expert opinion derived from survey data and a consensus workshop. CONCLUSION Until additional research from controlled trials becomes available, these evidence- and consensus-based treatment recommendations may be a useful approach to guide the use of antipsychotics in youth with aggression.
Collapse
|
33
|
Barnett SR, dosReis S, Riddle MA. Improving the management of acute aggression in state residential and inpatient psychiatric facilities for youths. J Am Acad Child Adolesc Psychiatry 2002; 41:897-905. [PMID: 12162625 DOI: 10.1097/00004583-200208000-00007] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
The Maryland Youth Practice Improvement Committee for Mental Health, which includes academicians, clinicians, and policymakers, was convened by the Maryland State Mental Hygiene Administration to advise on approaches to improve mental health care for youths in state inpatient and residential facilities. This report describes the development of a guide to improve the management of acute aggression. The process included the identification of key stakeholders, a literature review on managing acute aggression and promoting staff behavioral change, and many debates among the Committee members. An external peer review critiqued the Guide for content validity and feasibility in routine practice. The therapeutic process, a model to direct clinical decision-making used in other medical fields, forms the theoretical framework. Three levels of aggression and corresponding treatment options were established. The Committee hopes that acute aggressive episodes requiring restrictive interventions can be reduced with the combination of careful planning, adequate resources, and sufficient training. When selecting an intervention, the safety of all individuals involved is of primary importance and a patient's past stated preferences should also be considered. This report concludes with a brief discussion of future plans for the implementation and evaluation of this protocol in clinical practice.
Collapse
|
34
|
Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002; 41:26S-49S. [PMID: 11833633 DOI: 10.1097/00004583-200202001-00003] [Citation(s) in RCA: 445] [Impact Index Per Article: 20.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
This practice parameter describes treatment with stimulant medication. It uses an evidence-based medicine approach derived from a detailed literature review and expert consultation. Stimulant medications in clinical use include methylphenidate, dextroamphetamine, mixed-salts amphetamine, and pemoline. It carries FDA indications for treatment of attention-deficit/hyperactivity disorder and narcolepsy.
Collapse
|
35
|
Grcevich S. SLI381: a long-acting psychostimulant preparation for the treatment of attention-deficit hyperactivity disorder. Expert Opin Investig Drugs 2001; 10:2003-11. [PMID: 11772303 DOI: 10.1517/13543784.10.11.2003] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
SLI381 (Adderall-XR) is a longer-acting form of Adderall, a compound of mixed amphetamine salts that is now the most frequently prescribed brand of psychostimulant medication for attention-deficit hyperactivity disorder (ADHD) in the US. It has been demonstrated to be a safe and effective treatment for ADHD in school-age children. To date, the efficacy of SLI381 has been evaluated in controlled studies of over 500 patients. The therapeutic effects of SLI381 on the core symptoms of ADHD, as well as the duration of action of the formulation, have been demonstrated to persist for 12 h, with both greater efficacy and duration of effects seen at higher doses. Both behavioural and cognitive performance measures are improved throughout the school day and into post-school activities. The incidence of common stimulant-emergent side effects with SLI381 was no different than that seen with the existing Adderall preparation. Additionally, the frequency with which most stimulant-related side effects were experienced did not demonstrate a consistent dose-related incidence, with the exception of anorexia. SLI381 received a letter of approvability in August 2001 and will probably be approved in the immediate future by the US FDA. This formulation represents a valuable addition to the available pharmacotherapeutic options for ADHD by providing an amphetamine-based stimulant offering the advantages of once-daily dosing accompanied by the clinical benefits of ADHD symptom control associated with the now widely used Adderall preparation.
Collapse
Affiliation(s)
- S Grcevich
- Division of Child and Adolescent Psychiatry, University Hospitals of Cleveland, Cleveland, OH, USA
| |
Collapse
|
36
|
Abstract
Tourette syndrome (TS) is familial neuropsychiatric disorder that is characterized by motor and phonic tics that begin in childhood. Once thought of as a rare and debilitating disorder, in the last decade new scientific knowledge suggests that TS and related tic disorders are more common and less debilitating for the majority of individuals. Evidence points toward a spectrum of TS symptomatology that extends beyond the tics disorder to probably include obsessive-compulsive disorder, attention deficit hyperactivity disorder, and mood disorders. Tourette syndrome and its differential diagnosis are discussed in this article with a focus on new developments in classification, etiology, epidemiology, genetics, pathophysiology, and clinical management.
Collapse
Affiliation(s)
- D Marcus
- Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642-8673, USA
| | | |
Collapse
|
37
|
Kirby K, Floriani V, Bernstein H. Diagnosis and management of attention-deficit/ hyperactivity disorder in children. Curr Opin Pediatr 2001; 13:190-9. [PMID: 11317065 DOI: 10.1097/00008480-200104000-00019] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- K Kirby
- Massachusetts College of Pharmacy and Health Sciences, Boston, Massachusetts, USA.
| | | | | |
Collapse
|
38
|
Daviss WB, Bentivoglio P, Racusin R, Brown KM, Bostic JQ, Wiley L. Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry 2001; 40:307-14. [PMID: 11288772 DOI: 10.1097/00004583-200103000-00010] [Citation(s) in RCA: 115] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE To determine whether bupropion sustained release (SR) is effective and well-tolerated in adolescents with comorbid attention-deficit/hyperactivity disorder (ADHD) and depression. METHOD Subjects were 24 adolescents (aged 11-16 years old) with ADHD and either major depressive disorder or dysthymic disorder. After a 2-week, single-blind placebo lead-in, subjects were treated for 8+ weeks with bupropion SR at doses flexibly titrated up to 3 mg/kg b.i.d. (mean final doses: 2.2 mg/kg q A.M. and 1.7 mg/kg q P.M.). Outcomes were global improvement in ADHD and depression (clinician-rated), along with changes in depressive symptomatology (parent- and child-rated), ADHD symptomatology (parent- and teacher-rated), and functional impairment (parent-rated). RESULTS Clinicians rated 14 subjects (58%) responders in both depression and ADHD, 7 (29%) responders in depression only, and 1 (4%) a responder in ADHD only. Compared with post-placebo ratings, final parents' (p < .0005) and children's (p = .016) ratings of depressive symptomatology improved significantly, as did parents' (p < .0005) but not teachers' (p = .080) ratings of ADHD symptomatology. Final ratings of functional impairment improved significantly from enrollment (p < .0005). No subject discontinued medication because of side effects. CONCLUSIONS Bupropion SR may be effective and well-tolerated in adolescents with comorbid ADHD and depressive disorders. However, randomized, placebo-controlled studies are needed.
Collapse
Affiliation(s)
- W B Daviss
- Department of Psychiatry, Dartmouth Medical School, Hanover, NH, USA.
| | | | | | | | | | | |
Collapse
|
39
|
Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M, Arnold LE, Abikoff HB, Bukstein OG, Conners CK, Elliott GR, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, Kraemer HC, March JS, Newcorn JH, Severe JB, Wells K, Wigal T. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry 2001; 40:180-7. [PMID: 11211366 DOI: 10.1097/00004583-200102000-00012] [Citation(s) in RCA: 195] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVE Results of the NIMH Collaborative Multisite Multimodal Treatment Study of Children With Attention-Deficit/Hyperactivity Disorder (MTA) were analyzed to determine whether a double-blind, placebo-controlled methylphenidate (MPH) titration trial identified the best MPH dose for each child with attention-deficit/hyperactivity disorder (ADHD). METHOD Children with ADHD assigned to MTA medication treatment groups (n = 289) underwent a controlled 28-day titration protocol that administered different MPH doses (placebo, low, middle, and high) on successive days. RESULTS A repeated-measures analysis of variance revealed main effects for MPH dose with greater effects on teacher ratings of impairment and deportment (F3 = 100.6, n = 223, p = .0001; effect sizes 0.8-1.3) than on parent ratings of similar endpoints (F3 = 55.61, n = 253, p = .00001; effect sizes 0.4-0.6). Dose did not interact with period, dose order, comorbid diagnosis, site, or treatment group. CONCLUSIONS The MTA titration protocol validated the efficacy of weekend MPH dosing and established a total daily dose limit of 35 mg of MPH for children weighing less than 25 kg. It replicated previously reported MPH response rates (77%), distribution of best doses (10-50 mg/day) across subjects, effect sizes on impairment and deportment, as well as dose-related adverse events.
Collapse
Affiliation(s)
- L L Greenhill
- Clinical Psychiatry, Department of Psychiatry, Columbia University, New York, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Pliszka SR, Greenhill LL, Crismon ML, Sedillo A, Carlson C, Conners CK, McCracken JT, Swanson JM, Hughes CW, Llana ME, Lopez M, Toprac MG. The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part I. Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 2000; 39:908-19. [PMID: 10892234 DOI: 10.1097/00004583-200007000-00021] [Citation(s) in RCA: 80] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
OBJECTIVES Expert consensus methodology was used to develop evidence-based, consensually agreed-upon medication treatment algorithms for attention-deficit/hyperactivity disorder (ADHD) in the public mental health sector. Although treatment algorithms for adult mental disorders have been developed, this represents one of the first attempts to develop similar algorithms for childhood mental disorders. Although these algorithms were developed initially for the public sector, the goals of this approach are to increase the uniformity of treatment and improve the clinical outcomes of children and adolescents with ADHD in a variety of treatment settings. METHOD A consensus conference of academic clinicians and researchers, practicing clinicians, administrators, consumers, and families was convened to develop evidence-based consensus algorithms for the pharmacotherapy of childhood ADHD. After a series of presentations of current research evidence and panel discussion, the consensus panel met and drafted the algorithms along with guidelines for implementation. RESULTS The panel developed consensually agreed-upon algorithms for ADHD with and without specific comorbid disorders. The algorithms consist of systematic strategies for psychopharmacological interventions and tactics to ensure successful implementation of the strategies. While the algorithms focused on the medication management of ADHD, the conference emphasized that psychosocial treatments are often a critical component of the overall management of ADHD. CONCLUSIONS Medication algorithms for ADHD can be developed with consensus. A companion article will discuss the implementation of these algorithms.
Collapse
Affiliation(s)
- S R Pliszka
- Department of Psychiatry, University of Texas Health Science Center, San Antonio, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Millichap JG. Specific Language Impairment with or without ADHD. Pediatr Neurol Briefs 2000. [DOI: 10.15844/pedneurbriefs-14-7-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|